Impact of subanesthetic ketamine delivered via AmyloLipid nanovesicle (ALN)-based intranasal system on biobehavioral responses in an animal model of PTSD.

Transl Psychiatry · 2026 · PMC13043687 · PMID 41876451

Europe PMC DOI

hedged sentence

0.0530

closest p · 1.1× alpha

0.0530

boldest claim

The sentences

a trend toward significancep = 0.053so close (0.05 < p ≤ 0.1)

The 0.6 mg/kg ketamine-ALN PSS-exposed group exhibited a 45.45% MBR prevalence, showing a trend toward significance compared to the regular ketamine group (Fisher’s exact test, p = 0.053), where no MBR cases were observed.

also in 3,729 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.